Michael Mingueneau
Vice President & Head of Immunology Sail Bio
Michael Mingueneau is the Head of Immunology at Sail, where his responsibilities have included establishing a comprehensive understanding of the immunological properties of Sail’s eRNA platform while building out the company’s immunology unit and pipeline. Michael joined Sail from Biogen, where he held positions of increasing responsibility in the Immunology, Multiple Sclerosis, and Neuroimmunology departments over a period of ten years. At Biogen, as the Head of Immunology and Neuroimmunology unit, he led advancement of several antibody and small molecule programs from early discovery to R2D transition/Ph.1, including BIIB091 BTK inhibitor currently in phase 2 trial in Multiple Sclerosis patients. Before Biogen, Michael completed his postdoctoral training in the laboratories of Drs. C. Benoist and D. Mathis (Harvard Medical School, Boston, US) following a Ph.D. in Immunology with Drs. B. and M. Malissen (CIML & Aix-Marseille University, France). Michael’s work has resulted in publications in Nature Immunology, Immunity, Science, Blood, Journal of Exp Medicine, Journal of Allergy and Clinical Immunology, among others.
Seminars
- In vivo CAR-T cell engineering has the potential to transform the care of patients with autoimmune diseases by simplifying and broadening access to treatments with potential for cures
- Engineering an in vivo CAR-T drug candidate (DC) and extensively optimized to achieve an optimal dose efficiency profile and ultimately therapeutic index in patients with autoimmune conditions. As a result, in vivo CAR-T DC can achieve deep tissue depletion of B cells and effectively reset the B cell compartment at low dose levels
- In vivo CAR-T DC has the potential to replace complex, costly, and genome-integrative cell therapy products with an off-theshelf and non-integrative IV injectable product that avoids the safety risks associated with lymphoablative conditioning
